Wartość diagnostyczna poziomu NSE, białka S-100β i markerów zapalnych w krwi u pacjentów z epilepsją

BACKGROUND: To sodium valproate lore the effects of sodium valproate on serum inflammatory factors and s-100<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span> levels in patients with emergency secondary epilepsy(SE). METHODS: This was a retrospective cohort of 120 patients with SE who received Sodium valproate compared with a group who received carbamazepine for different therapeutic drugs. The general data, interleukin (IL)-2, IL-8, tumour necrosis factor (TNF)-<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span>, neuron-specific enolase (NSE), serum acid calcium-binding protein s-100<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>, total effective rate (TER), seizure onset condition, and adverse reactions (Ars) of the two groups were compared at baseline and at 3 months later. RESULTS: There were no significant differences in age, gender, BMI, course of the disease, stroke type, or seizure type between the study groups (P&gt; 0.05). The results showed that IL-2 of the Sodium valproate group (53.17± 4.95 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) was lower versus Carbamazepine group (62.38± 4.83 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) (P&lt; 0.05). The IL-8 of the Sodium valproate group postoperatively (26.48± 2.73 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) was lower versus the Carbamazepine group (33.54± 3.39 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) (P&lt; 0.05). Postoperatively, the TNF-<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span> in Sodium valproate group (32.18± 4.26 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) was lower versus the Carbamazepine group (41.03± 4.92 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) (P&lt; 0.05). The s-100<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span> (0.29 ± 0.15 ) <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L in the Sodium valproate group was lower versus the Carbamazepine group (0.54± 0.14) <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L (P &lt; 0.05). The TER of the Sodium valproate group (93.33% ) was higher versus the Carbamazepine group of 75% (P &lt; 0 .0 5 ). The number of epileptic seizures in the Sodium valproate group was 0.81± 0.08 times per year versus 1.23± 0.12 times per year in the Carbamazepine group. The duration of epilepsy in the Sodium valproate group (2.53± 0.22 min/time) was shorter than that in the Carbamazepine group (3.08 ± 0.24 min/time). CONCLUSIONS: Sodium valproate can drastically relieve the epileptic symptoms of patients with SE, and there was no great difference in ARs. Hence, it is safe and worthy of popularization and application.